Objective To explore the research of proteomics technology in the diagnosis of cardiovascular and cerebrovascular diseases, and its effect in improving early detection of diseases, accurate diagnosis, and disease classification. Methods 100 patients from July 2022 to December 2022 were selected and divided into control group and observation group according to their condition. Each group received detailed proteomics testing. Liquid chromatography-mass spectrometry (LC-MS/MS) combined with bioinformatics analysis methods were used to conduct in-depth research on changes in protein expression profiles. Compare the protein differences between the 2 groups and analyze the correlation based on clinical characteristics. Results Proteomic testing identified specific protein markers closely related to cardiovascular and cerebrovascular diseases. The observation group found that the expression levels of some proteins were significantly higher than those in the control group. The sensitivity and specificity of protein markers are significantly enhanced, which is beneficial to early detection of diseases and personalized treatment strategies. Conclusion Proteomics technology can be effectively used in the diagnosis of cardiovascular and cerebrovascular diseases, providing support for the development of precision medicine. Dynamic monitoring of protein levels can improve disease diagnosis and provide a reliable basis for clinical diagnosis.

cardiovascular and cerebrovascular diseases  /  proteomics  /  diagnosis  /  biomarker